ShoreHaven Wealth Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

ShoreHaven Wealth Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,794	Closed	-$247K	–	73
2021 Q4	$247K	Sell	1,794 -15	-0.8%	-$1.91K	0.12%	42
2021 Q3	$251K	Sell	1,809 -630	-26%	-$78.7K	0.13%	40
2021 Q2	$236K	Hold	2,439	–	–	0.13%	48
2021 Q1	$167K	Sell	2,439 -530	-18%	-$42.9K	0.09%	61
2020 Q4	$255K	Buy	+2,969	New	+$252K	0.14%	43

Other funds holding BHVN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

ShoreHaven Wealth Partners's BHVN Position: Q1 2022 in Review

ShoreHaven Wealth Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 1,794 shares — an estimated $247K sold.

ShoreHaven Wealth Partners first reported a position in BHVN in Q4 2020 and held it in 5 quarters. The position peaked at $255K in Q4 2020. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

ShoreHaven Wealth Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
ShoreHaven Wealth Partners sold 1,794 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $247K.
ShoreHaven Wealth Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 5 quarters.
ShoreHaven Wealth Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $255K in Q4 2020.
307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on ShoreHaven Wealth Partners's 13F filing for Q1 2022, filed 13 May 2022.